Hadassah

Initiated in Israel, Clinical Trial for Innovative Pancreatic Cancer Treatment Expands to United States

Saturday, Dec 1 2012

A clinical trial with TL-118--a new treatment for metastatic pancreatic cancer--that has been ongoing at the Hadassah University Medical Center and three other oncology centers in Israel, has been expanded to the United States.

TL-118. produced by Tiltan Pharma Ltd., belongs to the family of angiogenesis-inhibiting drugs, which means it inhibits new blood vessel formation in tumors and thus cuts off their blood supply and growth. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer cells. Anti-angiogenic therapy has, therefore, emerged as a most promising strategy with solid tumors, which rely on aggressive angiogenesis for their growth.

The new United States trial will be conducted at White Plains (NY) Hospital, and will include patients who have been newly diagnosed with metastatic pancreatic cancer and not yet treated with any chemotherapy. A control group will receive standard chemotherapy, while the treatment group will receive TL-118 in addition to chemotherapy.

Dr. Dan Costin, Co-Medical Director of the White Plains Hospital cancer program and Principal Investigator for the TL-118 study at White Plains Hospital, related: "We are happy to introduce this cutting-edge therapy to our pancreatic cancer patients. Unfortunately, metastatic pancreatic cancer is a disease with very poor prognosis and we are urgently seeking new solutions that might enhance survival."

TL-118 was initially tested in a mouse model of pancreatic cancer. In these pre-clinical studies, TL-118 monotherapy inhibited tumor growth significantly, as compared to the standard-of-care chemotherapy. Moreover, when TL-118 therapy was combined with standard-of-care chemotherapy, the tumors were eliminated in all the treated animals.

To date, over 100 cancer patients have been treated with TL-118 for up to four years, according to Tiltan Pharma, jointly owned by Yissum, the Hebrew University's Technology Transfer Company, and other investors from Israel and Canada.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, May 23 2018

From Legacy to Innovation: The Vision of Hadassah’s New Division of Nursing Director

Rely Alon, PhD, the new director of the Hadassah Medical Organization’s Division of Nursing and Health Professions, has a vision: “to bring Hadassah’s nurses to the forefront of leadership and to the spearhead of nursing in Israel.”

READ MORE ›
alt_text

Monday, May 7 2018

Hadassah Cardiac Specialists Are Collaborating with Colleagues to Save Syrian Children

In an effort to save the lives of Syrian children suffering from life-threatening and complex heart abnormalities, the Hadassah Medical Organization and the Baruch Padeh Medical Center in Poriya-Tiberias have launched a unique collaboration as part of the Israel Defense Forces’ Good Neighbor program.

READ MORE ›
alt_text

Monday, May 7 2018

Pluristem Stem Cell Therapy, Based on Hadassah Preclinical Research, Has Been Cleared by FDA

Pluristem Therapeutics has announced that its new cell therapy to treat acute radiation syndrome (PLX-R18), based on the pioneering studies performed within the laboratory of Prof. Raphael Gorodetsky at the Hadassah Medical Organization, has received clearance from the United States Food and Drug Administration to treat individuals who may have been acutely exposed to high-dose radiation as the result of a nuclear attack or accident.

READ MORE ›
alt_text

Thursday, May 3 2018

HMO Exclusive Call with Nurse Rely Alon

Please join us for an exclusive conference call with Dr. Rely Alon, Director, Division of Nursing & Health Professions, Wednesday May 9, 2018 from 10:00 - 11:00 am EDT

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More